Lucid Cap Mkts upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks reports.
Several other equities research analysts also recently commented on the stock. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, July 8th. Wall Street Zen lowered Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 30th. Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research note on Wednesday, July 8th. HC Wainwright assumed coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They set a “buy” rating and a $9.00 price target on the stock. Finally, BTIG Research cut their price objective on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.
Read Our Latest Report on Tvardi Therapeutics
Tvardi Therapeutics Trading Up 1.6%
Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, equities analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current year.
Institutional Trading of Tvardi Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new position in shares of Tvardi Therapeutics during the second quarter worth $63,000. BlackRock Inc. purchased a new stake in Tvardi Therapeutics in the second quarter valued at $181,000. GSA Capital Partners LLP purchased a new stake in Tvardi Therapeutics in the second quarter valued at $34,000. XTX Topco Ltd acquired a new stake in Tvardi Therapeutics during the 4th quarter worth about $55,000. Finally, Quadrature Capital Ltd acquired a new stake in Tvardi Therapeutics during the 4th quarter worth about $90,000. Institutional investors and hedge funds own 44.66% of the company’s stock.
About Tvardi Therapeutics
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Read More
- Five stocks we like better than Tvardi Therapeutics
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
